Market Overview

Diplomat Pharmacy Reports Q2 Earnings Beat, Will Explore Strategic Alternatives

Diplomat Pharmacy Reports Q2 Earnings Beat, Will Explore Strategic Alternatives

Diplomat Pharmacy, Inc. (NYSE: DPLO) reported second-quarter earnings at $2.13 per share. The company reported revenue of $1,288 million, compared to $1,416 million last year.

Despite the positive earnings Diplomat Pharmacy has cut fiscal year 2019 sales guidance to $4.7 billion -$5 billion versus the $4.91 billion estimate.

The company also announced it is reviewing strategic alternatives.

"We continue to believe in our business model and long-term prospects and we remain encouraged by our pipeline for 2020, despite our reduced guidance for 2019,” said Brian Griffin, CEO of Diplomat. “We are pleased that infusion therapies continue to demonstrate strength and we are taking actions to improve our core specialty pharmacy business, rebuild our PBM and enhance our financial flexibility."

Diplomat Pharmacy shares were trading up 5.26% at $5.60 in Friday’s pre-market session. The stock has a 52-week high of $21.48 and a 52-week low of $4.17.

Related Links:

New York Times Reports Mixed Q2 Earnings

Party City Falls After Q2 Earnings Miss, Guidance Cut

Posted-In: Earnings M&A News Guidance Top Stories Best of Benzinga


Related Articles (DPLO)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Overstock Updates tZero, Blockchain Initiatives

Tribune Media Reports Mixed Q2 Earnings